Judge Rejects Aegerion Plea Deal for Deceptive Cholesterol Drug Marketing

Drug Industry Daily
A A
A federal judge blocked Aegerion’s proposed $36 million deal to settle claims of illegal marketing tactics for its cholesterol drug Juxtapid, ordering the case to trial.

To View This Article:

Login

Subscribe To Drug Industry Daily